{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:17:41Z","timestamp":1779196661138,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-025-00860-5","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:01:15Z","timestamp":1761969675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mecasermin for the treatment of Rett Syndrome: a systematic review"],"prefix":"10.1007","volume":"26","author":[{"given":"Fernanda Cristina Poscai","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luiza","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Campos","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1leff Mascarenhas","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrine Zambiazi","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana Khauam","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kleber Fernando","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"860_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","volume":"12","author":"U Petriti","year":"2023","unstructured":"Petriti U, Dudman DC, Scosyrev E et al (2023) Global prevalence of RTT: s ystematic review and meta-analysis. Syst Rev 12:5. https:\/\/doi.org\/10.1186\/s13643-023-02169-6","journal-title":"Syst Rev"},{"key":"860_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mrdd.10020","volume":"8","author":"B Hagberg","year":"2002","unstructured":"Hagberg B (2002) Clinical manifestations and stages of RTT. Ment Retard Dev Disabil Res Rev 8:61\u201365. https:\/\/doi.org\/10.1002\/mrdd.10020","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"860_CR3","doi-asserted-by":"publisher","first-page":"e41555","DOI":"10.7759\/cureus.41555","volume":"15","author":"DC Oluigbo","year":"2023","unstructured":"Oluigbo DC (2023) RTT: a Tale of altered genetics, synaptic plasticity, and neurodevelopmental dynamics. Cureus 15:e41555. https:\/\/doi.org\/10.7759\/cureus.41555","journal-title":"Cureus"},{"key":"860_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00450","volume":"10","author":"C Vahdatpour","year":"2016","unstructured":"Vahdatpour C, Dyer AH, Tropea D (2016) Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front Neurosci 10:450. https:\/\/doi.org\/10.3389\/fnins.2016.00450","journal-title":"Front Neurosci"},{"key":"860_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1358\/dot.2007.43.3.1079876","volume":"43","author":"SF Kemp","year":"2007","unstructured":"Kemp SF (2007) Mecasermin rinfabate. Drugs Today 43:149\u2013155. https:\/\/doi.org\/10.1358\/dot.2007.43.3.1079876","journal-title":"Drugs Today"},{"issue":"9","key":"860_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Trofinetide: first approval. Drugs 83(9):819\u2013824. https:\/\/doi.org\/10.1007\/s40265-023-01883-8","journal-title":"Drugs"},{"key":"860_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neulet.2016.04.024","volume":"621","author":"D Tropea","year":"2016","unstructured":"Tropea D, Mortimer N, Bellini S et al (2016) Expression of nuclear Methyl-CpG binding protein 2 (Mecp2) is dependent on neuronal stimulation and application of insulin-like growth factor 1. Neurosci Lett 621:111\u2013116. https:\/\/doi.org\/10.1016\/j.neulet.2016.04.024","journal-title":"Neurosci Lett"},{"key":"860_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","volume":"325","author":"AH Dyer","year":"2016","unstructured":"Dyer AH, Vahdatpour C, Sanfeliu A et al (2016) The role of insulin-like growth factor 1 (IGF-1) in brain development, maturation and neuroplasticity. Neuroscience 325:89\u201399. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.03.056","journal-title":"Neuroscience"},{"key":"860_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"860_CR10","doi-asserted-by":"publisher","first-page":"5073078","DOI":"10.1155\/2016\/5073078","volume":"2016","author":"G Pini","year":"2016","unstructured":"Pini G, Congiu L, Benincasa A et al (2016) Illness severity, social and cognitive ability, and EEG analysis of ten patients with RTT treated with Mecasermin (recombinant human IGF-1). Autism Res Treat 2016:5073078. https:\/\/doi.org\/10.1155\/2016\/5073078","journal-title":"Autism Res Treat"},{"key":"860_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/brainsci10080515","volume":"10","author":"C Keogh","year":"2020","unstructured":"Keogh C, Pini G, Gemo I et al (2020) Functional network mapping reveals state-dependent response to IGF1 treatment in RTT. Brain Sci 10:515. https:\/\/doi.org\/10.3390\/brainsci10080515","journal-title":"Brain Sci"},{"key":"860_CR12","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1073\/pnas.1311141111","volume":"111","author":"OS Khwaja","year":"2014","unstructured":"Khwaja OS, Ho E, Barnes KV et al (2014) Safety, pharmacokinetics, and preliminary assessment of efficacy of Mecasermin (recombinant human IGF-1) for the treatment of RTT. Proc Natl Acad Sci U S A 111:4596\u20134601. https:\/\/doi.org\/10.1073\/pnas.1311141111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"860_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/acn3.533","volume":"5","author":"HM O\u2019Leary","year":"2018","unstructured":"O\u2019Leary HM, Kaufmann WE, Barnes KV et al (2018) Placebo-controlled crossover assessment of Mecasermin for the treatment of RTT. Ann Clin Transl Neurol 5:323\u2013332. https:\/\/doi.org\/10.1002\/acn3.533","journal-title":"Ann Clin Transl Neurol"},{"key":"860_CR14","doi-asserted-by":"publisher","first-page":"868008","DOI":"10.3389\/fnins.2022.868008","volume":"16","author":"S Shovlin","year":"2022","unstructured":"Shovlin S, Delepine C, Swanson L et al (2022) Molecular signatures of response to Mecasermin in children with RTT. Front Neurosci 16:868008. https:\/\/doi.org\/10.3389\/fnins.2022.868008","journal-title":"Front Neurosci"},{"key":"860_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0896-6273(95)90171-X","volume":"15","author":"AK McAllister","year":"1995","unstructured":"McAllister AK, Lo DC, Katz LC (1995) Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 15:791\u2013803. https:\/\/doi.org\/10.1016\/0896-6273(95)90171-X","journal-title":"Neuron"},{"issue":"3","key":"860_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nn.2505","volume":"13","author":"Y Ji","year":"2010","unstructured":"Ji Y, Lu Y, Yang F et al (2010) Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat Neurosci 13(3):302\u2013309. https:\/\/doi.org\/10.1038\/nn.2505","journal-title":"Nat Neurosci"},{"key":"860_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnsyn.2014.00005","volume":"6","author":"Y Kellner","year":"2014","unstructured":"Kellner Y, G\u00f6decke N, Dierkes T et al (2014) The BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal activity. Front Synaptic Neurosci 6:5. https:\/\/doi.org\/10.3389\/fnsyn.2014.00005","journal-title":"Front Synaptic Neurosci"},{"key":"860_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neures.2022.05.008","volume":"183","author":"A Goto","year":"2022","unstructured":"Goto A (2022) Synaptic plasticity during systems memory consolidation. Neurosci Res 183:1\u20136. https:\/\/doi.org\/10.1016\/j.neures.2022.05.008","journal-title":"Neurosci Res"},{"key":"860_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a005710","volume":"4","author":"C L\u00fcscher","year":"2012","unstructured":"L\u00fcscher C, Malenka RC (2012) NMDA receptor-dependent long-term potentiation and long-term depression (LTP\/LTD). Cold Spring Harb Perspect Biol 4:a005710. https:\/\/doi.org\/10.1101\/cshperspect.a005710","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"860_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrn2699","volume":"10","author":"A Holtmaat","year":"2009","unstructured":"Holtmaat A, Svoboda K (2009) Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 10:647\u2013658. https:\/\/doi.org\/10.1038\/nrn2699","journal-title":"Nat Rev Neurosci"},{"key":"860_CR21","doi-asserted-by":"publisher","first-page":"9941","DOI":"10.1073\/pnas.1311685111","volume":"111","author":"J Castro","year":"2014","unstructured":"Castro J, Garcia RI, Kwok S et al (2014) Functional recovery with Recombinant human IGF1 treatment in a mouse model of RTT. Proc Natl Acad Sci U S A 111:9941\u20139946. https:\/\/doi.org\/10.1073\/pnas.1311685111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"860_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/2040-2392-4-9","volume":"4","author":"O Bozdagi","year":"2013","unstructured":"Bozdagi O, Tavassoli T, Buxbaum JD (2013) Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism 4:9. https:\/\/doi.org\/10.1186\/2040-2392-4-9","journal-title":"Mol Autism"},{"key":"860_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00335-019-09793-5","volume":"30","author":"N Vashi","year":"2019","unstructured":"Vashi N, Justice MJ (2019) Treating RTT: from mouse models to human therapies. Mamm Genome 30:90\u2013110. https:\/\/doi.org\/10.1007\/s00335-019-09793-5","journal-title":"Mamm Genome"},{"key":"860_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-222","volume":"9","author":"KK Mestan","year":"2011","unstructured":"Mestan KK, Ilkhanoff L, Mouli S et al (2011) Genomic sequencing in clinical trials. J Transl Med 9:222. https:\/\/doi.org\/10.1186\/1479-5876-9-222","journal-title":"J Transl Med"},{"key":"860_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/hmg\/ddm007","volume":"16","author":"V Deng","year":"2007","unstructured":"Deng V, Matagne V, Banine F et al (2007) FXYD1 is an MeCP2 target gene overexpressed in the brains of RTT patients and Mecp2-null mice. Hum Mol Genet 16:640\u2013650. https:\/\/doi.org\/10.1093\/hmg\/ddm007","journal-title":"Hum Mol Genet"},{"key":"860_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnins.2020.00020","volume":"14","author":"ZF Yuan","year":"2020","unstructured":"Yuan ZF, Mao SS, Shen J et al (2020) Insulin-like growth factor-1 down-regulates the phosphorylation of FXYD1 and rescues behavioral deficits in a mouse model of RTT. Front Neurosci 14:20. https:\/\/doi.org\/10.3389\/fnins.2020.00020","journal-title":"Front Neurosci"},{"key":"860_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tips.2023.06.008","volume":"44","author":"H Parent","year":"2023","unstructured":"Parent H, Ferranti A, Niswender C (2023) Trofinetide: a pioneering treatment for Rett syndrome. Trends Pharmacol Sci 44:740\u2013741. https:\/\/doi.org\/10.1016\/j.tips.2023.06.008","journal-title":"Trends Pharmacol Sci"},{"key":"860_CR28","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA et al (2023) Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med 29:1468\u20131475. https:\/\/doi.org\/10.1038\/s41591-023-02398-1","journal-title":"Nat Med"},{"key":"860_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M et al (1999) RTT is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185\u2013188. https:\/\/doi.org\/10.1038\/13810","journal-title":"Nat Genet"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/08830738030180100901","volume":"18","author":"J Christodoulou","year":"2003","unstructured":"Christodoulou J, Weaving LS (2003) MECP2 and beyond: phenotype\u2013genotype correlations in RTT. J Child Neurol 18:669\u2013674. https:\/\/doi.org\/10.1177\/08830738030180100901","journal-title":"J Child Neurol"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-025-00860-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T04:04:57Z","timestamp":1769400297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-025-00860-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s10048-025-00860-5","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}